Cardiff Oncology Q1 net loss narrows as operating expenses fall

Cardiff Oncology

14/05/2026 23:19

Overview

US cancer therapy developer's Q1 royalty revenue declined yr/yr

Net loss for Q1 narrowed compared to prior year

Operating expenses fell, mainly due to lower R&D costs

Outlook

Company expects current cash resources to fund operations into Q1 2027

Cardiff Oncology to share additional Phase 3 trial details and regulatory strategy in mid-2026

Company to present updated Phase 2 trial data at ASCO Annual Meeting in late May 2026

Result Drivers

LOWER R&D SPENDING - Q1 operating expenses fell mainly due to a $3.7 mln decrease in R&D costs, primarily clinical trial and preclinical activities

HIGHER SG&A COSTS - SG&A expenses rose by $2.1 mln, mainly due to employee severance agreements and stock option modifications

Company press release: ID:nGNX26YNPk

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Royalty Revenue
$41,000
Q1 Basic EPS
-$0.18


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cardiff Oncology Inc is $10.00, about 478% above its May 14 closing price of $1.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)